Poll Link: mLABU
Biotech stocks have been on fire recently as many are delivering on investor expectations by announcing breakthrough clinical results or introducing revolutionary medicine. COVID-19 vaccines were made in record time. Rapid development and regulatory approvals will continue to play a crucial role in biotech’s market performance. With each milestone achieved in treatment or drug development, top biotech stocks will continue to thrive.
Whitelisting mLABU will provide our community the ability to participate in price exposure to a diversified basket of US Biotech Companies at 300% of the daily performance of its benchmark index all in one mASSET. The benchmark index, S&P Biotechnology Select Industry Index (XBI), is a basket of equal-weighted companies chosen by market cap. The fund is concentrated (not diversified) as the majority of holdings in this basket are Biotechnology & Medical Research companies but it also captures significant exposure to Pharmaceuticals as well.
At the time of writing, LABU’s YTD Return is 46.36%, with 172 holdings and 1 year annualized total return is 196.41%. Over the past 5 years, LABU has generated an average annualized return of 40.8%.
The NYSE-listed fund charges a steep fee in comparison to most levered ETFs but a huge benefit of whitelisting mLABU will be participation in only the price exposure.
Thanks for viewing this proposal. I appreciate your consideration and hope you will vote Yes in support of Poll #68.